Dolantin (Pethidine/Meperidine) is a synthetic analgesic that is generally applied in clinical settings that require support for the management of high-intensity, acute pain. Its therapeutic role centers on providing short-term symptomatic support across several main clinical domains.

The medication is applied to address episodes of severe or moderate to severe discomfort, such as pain stemming from trauma or acute internal discomfort. The medication is used to provide supportive pain relief in preoperative, postoperative, and childbirth scenarios.

Quick Fact: Supportive Management for Severe Discomfort

This supportive medication is applied when symptomatic manifestations are pronounced and interfere significantly with stability. It plays a role in managing symptoms where the patient experiences heightened physiological strain, which supports the patient during difficult episodes by easing distress.

“The primary benefit is that it provides supportive relief for acute discomfort in situations where patients experience pronounced symptoms.”

This focus on acute, intense pain means the medication is relevant when short-term symptomatic assistance is needed across domains involving significant symptom expression.

Eligibility Profile of Pethidine (Dolantin) — Official Regulatory Information

Official regulatory documents define strict criteria for the use of pethidine, which is commercially known as Dolantin or Demerol, primarily based on patient health status and concurrent treatments.

Contraindicated Populations (Must Not Use)
Known hypersensitivity to the drug or its components
Concurrent use of Monoamine Oxidase Inhibitors (MAOIs), or use within the last 14 days
Severe respiratory depression or acute/severe bronchial asthma
Severe renal impairment or severe hepatic impairment (risk of toxic metabolite accumulation)
Convulsive states (e.g., status epilepticus) or increased intracranial pressure
Patients with pre-eclampsia/eclampsia or acute alcoholism

Restricted or Conditional Use
Older Adults/Elderly: Use is generally not recommended due to increased sensitivity and higher risk of toxicity from the metabolite, normeperidine. Initial doses must be significantly reduced.
Pediatric Use: Allowed for acute pain and premedication, but specific regulatory labels state that safety and efficacy are not established for children under 18.
Pregnancy/Lactation: Use during labor is documented, but the drug crosses the placenta and may cause neonatal respiratory depression. Use earlier in pregnancy is generally not established as safe. Excreted into breast milk; use with caution.
Chronic Pain Management: Use is officially not recommended for prolonged periods due to the risk of normeperidine accumulation and toxicity.

Interactions with other medicines and products

The interaction profile of Dolantin (Pethidine) is characterized by several officially documented restrictions, primarily due to the risk of severe pharmacodynamic and pharmacokinetic consequences.

---

Contraindicated and Restricted Combinations

Classification	Interacting Substance/Class	Constraint Summary
Contraindicated	Monoamine Oxidase Inhibitors (MAOIs)	Must not be co-administered; a mandatory separation window of 14 days is required after stopping the MAOI.
Avoidance Advised	Mixed Agonist/Antagonist Opioids (e.g., Nalbuphine, Pentazocine)	Use may reduce the analgesic effect and may precipitate withdrawal symptoms.
High Risk	Ritonavir	Concomitant use increases the risk of elevating the toxic metabolite, Normeperidine.

---

Pharmacodynamic and Metabolic Interactions

Co-administration with other Central Nervous System (CNS) Depressants (including alcohol and benzodiazepines) carries a documented risk of additive pharmacodynamic effects, leading to profound sedation and respiratory depression. The combination of Pethidine with serotonergic drugs (such as SSRIs and SNRIs) is associated with an increased regulatory warning for Serotonin Syndrome.

From a metabolic perspective, the drug’s exposure is modulated by the CYP3A4 enzyme system. CYP3A4 inhibitors may increase Pethidine plasma concentration, while CYP3A4 inducers may potentially increase the level of the neurotoxic metabolite, Normeperidine. Additionally, Cimetidine is documented to reduce Pethidine's metabolism, resulting in increased plasma concentration.

Population-Specific Constraints

The risk associated with interaction-mediated toxicity is officially documented to be heightened in specific populations. Pethidine is contraindicated or requires extreme caution in patients with renal impairment due to the significantly increased potential for Normeperidine accumulation.

Dolantin functions as a full agonist at the mu-opioid receptor ( MOR), a G i/ o-protein coupled receptor ( GPCR) expressed widely throughout the central and peripheral nervous systems. The molecule binds reversibly to the orthosteric site on the receptor, inducing a conformational change that activates the intracellular signaling cascade.

the

Activation of the GPCR complex promotes the dissociation of the G i/ o subunit. This event leads to two concurrent intracellular effects: inhibition of adenylyl cyclase and activation of inwardly rectifying potassium channels ( K ir). The inhibition of adenylyl cyclase reduces intracellular levels of cyclic adenosine monophosphate ( cAMP). Simultaneously, the activated K ir channels promote the efflux of potassium ions ( K^+), resulting in neuronal hyperpolarization.

These combined biochemical effects decrease the release of excitatory neurotransmitters from the presynaptic terminal and reduce the postsynaptic neuron's capacity to generate action potentials. This pharmacodynamic mechanism modulates neurotransmission within key ascending and descending pathways, leading to an overall change in the electrophysiological state of the targeted neurons.

The use of Dolantin (Pethidine or Meperidine) is defined by instructions governing its administration, dosing, and duration. The medicine can be administered through parenteral routes, including intramuscular (IM), subcutaneous (SC), or slow intravenous (IV) injection, as well as orally via tablet or solution.

For adult pain relief, the standard dosing regimen is 50 mg to 150 mg, administered on an as-needed basis, typically repeated every three to four hours. This frequency is tightened for contexts such as obstetrical analgesia, where 50 mg to 100 mg may be administered at one to three hour intervals. The total administered dosage must adhere to a maximum limit of 600 mg within a 24-hour period.

A crucial procedural constraint is the mandated short-term use only; the drug is not intended for chronic pain management. Administration procedures include specific steps, such as diluting the oral solution in one-half glass of water before intake, and administering IV injections very slowly while the patient is preferably lying down. A reduced initial dosage is generally required for specific populations, including older adults and patients with hepatic or renal impairment. These instructions define the standardized approach to using the medicine.

Dolantin: Recent Clinical Evidence

1. Evidence for the Relief of Severe Acute Pain

The core research for Dolantin was studied for its application in managing severe or moderate to severe acute pain. This field is supported by the existence of Randomized Controlled Trials (RCTs) and systematic reviews. These studies were applied in examining patient-reported experiences of pain, primarily in adult and adolescent populations. Researchers studied short-term outcomes related to physical discomfort. Research provides insight into short-term changes but data for long-term outcomes remain insufficient for persistent pain conditions.

2. Research on Pain Management During Childbirth

Dolantin was evaluated in numerous clinical studies specifically for its use during labor, making this a well-researched area. The evidence base includes RCTs and retrospective cohort studies, which examined outcomes for both the mother and the newborn. For mothers, researchers studied patient-reported outcomes describing perceived discomfort. Findings describe patterns observed in these studies, with some trials reporting variations in the measured outcomes related to physical discomfort compared to other analgesic options used during labor.

3. Study of Use in Perioperative Settings and for Shivering

Dolantin was studied for its application in the perioperative context, which includes the period before, during, and after surgical procedures. Specific research has explored whether it can influence the onset of involuntary muscle movements (shivering) that may occur as patients recover from anesthesia. Studies monitored the intensity and frequency of shivering using specific grading scales. The data show patterns related to how the frequency or intensity of shivering was measured in patients; however, research on its influence on shivering is ongoing.

4. Evidence in Special Populations and Research Gaps

Research has explored the use of Dolantin in various special populations, including pediatric patients and older adult populations, noting that data for these groups remain insufficient for robust comparisons. Follow-up durations were limited in many trials, meaning data for long-term outcomes are still emerging. Comparative evidence is lacking in some areas when looking at newer alternatives. Additionally, the evidence base primarily consists of single-dose studies, and data are still emerging regarding its role in conditions characterized by persistent or chronic pain, as the research focus is overwhelmingly on acute, disruptive episodes.

Common questions about Dolantin (FAQ)

Q: Why is Dolantin only available by prescription?

Dolantin is classified as an opioid analgesic and a controlled substance (often Schedule II in the US). This classification stems from the documented risks of addiction, abuse, and misuse. Because of these risks, regulatory programs such as the Opioid Analgesic REMS require its distribution to be tightly controlled and limited to prescription-only use.

---

Q: How long does the effect of one dose of Dolantin typically last?

Official information indicates that the duration of its pain-relieving effect is generally short-acting compared to some other medicines in its class. For all administration routes, the analgesic action is typically reported to last between two and four hours.

---

Q: What should I do if I experience a rash while taking Dolantin?

Regulatory documents list a rash, hives, or itching as possible adverse effects of the medicine. If a patient observes any new or worsening symptoms, including a rash, official information advises consulting a healthcare provider for proper assessment.

---

Q: Does Dolantin show up on standard drug tests?

Yes, regulatory and medical information confirms that Dolantin (Meperidine) is an opioid. It may therefore be detected on standard drug screening tests specifically designed to identify this class of medication or its metabolites, which are breakdown products of the drug.

---

Q: What does 'contraindication' mean in relation to Dolantin?

In official drug labels, a contraindication is a specific condition or circumstance where the prescribing information strongly advises against using the drug. For Dolantin, this term identifies situations where taking the medicine presents a known, severe risk that outweighs any possible benefit, such as having certain existing health conditions or taking specific interacting drugs.

---

Q: How does Dolantin compare to other medicines in the same class?

Regulatory summaries note that the main differences among various opioids generally relate to their potency and pharmacokinetic profile (how the body handles them). Dolantin is noted for its characteristically rapid onset of pain relief but also its short duration of action when compared to many other prescription opioids.

---

Q: How quickly does Dolantin start working after taking it?

The onset of effect is highly dependent on the way the medicine is administered. Regulatory data suggests the onset is typically one minute for intravenous (IV) injection. For intramuscular (IM), subcutaneous (SC), and oral administration, the onset is generally reported to be between 10 and 15 minutes.

---

Q: Does Dolantin interact with common over-the-counter pain relievers?

Official information indicates that Dolantin is sometimes used in an alternating regimen alongside nonopioid analgesics to manage pain. These nonopioids can include common over-the-counter medicines like acetaminophen, aspirin, or NSAIDs (Non-Steroidal Anti-Inflammatory Drugs). This combined use is typically overseen by a healthcare professional to improve pain control while using the lowest effective opioid dosage.

---

Q: Can I take Dolantin with herbal supplements like St. John's Wort?

Regulatory warnings specifically advise caution regarding interactions with the herbal product St. John’s Wort. This is because St. John’s Wort may affect the enzymes that metabolize (break down) the medicine in the body and can also interfere with neurotransmitter levels, increasing the risk of certain adverse reactions.

---

Q: What are the considerations for using Dolantin during pregnancy?

Official information indicates that prolonged use of Dolantin during pregnancy can result in the newborn developing Neonatal Opioid Withdrawal Syndrome (NOWS). Furthermore, use during labor is associated with potential respiratory depression in the newborn. The drug is classified to require caution and careful risk assessment regarding its use during pregnancy.

---

Q: Can I drive a car while taking Dolantin?

Due to common side effects like dizziness, sedation, and confusion, official guidance notes that caution is warranted regarding activities that require full mental alertness. This includes driving a car or operating heavy machinery until an individual is aware of how the medicine affects their ability to perform such activities.

---

Q: Does Dolantin have a 'black box' warning from regulatory bodies?

Yes, official prescribing information typically requires a Boxed Warning (often called a 'black box' warning) to be prominently displayed on the label. This warning highlights the serious and potentially life-threatening risks associated with the medicine, including addiction, abuse, misuse, and severe respiratory depression.

---

Q: Are there any specific lab tests recommended while taking Dolantin?

Regulatory documents highlight the risk of normeperidine accumulation in patients with reduced kidney function. Due to this risk, certain regulatory information indicates that a healthcare provider may need to monitor a patient's kidney function (renal status) during treatment.

---

Q: What are the signs of taking too much Dolantin?

Taking too much of the medicine can lead to severe, life-threatening effects that are described in the regulatory safety profile. These signs of excessive administration can include profound respiratory depression (shallow, slow, or difficult breathing) and circulatory depression.

Official Storage and Disposal Requirements

Dolantin (Meperidine/Pethidine), an opioid analgesic, is subject to specific regulatory guidelines for storage and disposal to maintain stability and prevent unauthorized access.

Storage/Disposal Component	Official Regulatory Requirement
Temperature and Handling	Store at Controlled Room Temperature (20 C to 25 C); keep from freezing and away from excess heat. The product must be protected from light [3.4].
Container and Security	Keep the medicine in its original, tightly closed container and store it in a safe, secure place, strictly out of sight and reach of children [2.1, 1.1].
Stability After Opening	For multiple-dose vials of injection, discard any unused portion after 28 days of initial use. Single-dose products must be discarded after a single use [4.2].
Disposal Instructions	The preferred method is disposal through a medicine take-back program. If unavailable, unused tablets or oral solution must be immediately flushed down the toilet, as officially directed for this controlled substance [2.1, 2.2].

These statements define how the product must be stored, protected, handled, and disposed of according to authoritative governmental labeling.